Radiopharmaceutical Treatment of Advanced Kidney Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

January 30, 2028

Study Completion Date

January 1, 2029

Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
DRUG

177Lu-PSMA-617

Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK